[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ARF1

Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus Cytoplasm, perinuclear region Cell junction, synapse, synaptosome Cell junction, synapse, postsynaptic cell membrane, postsynaptic density Membrane Lipid-anchor
Domain PF00025 ADP-ribosylation factor family
Function

GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD).

> Gene Ontology
 
Biological Process GO:0002028 regulation of sodium ion transport
GO:0002090 regulation of receptor internalization
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002697 regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006814 sodium ion transport
GO:0006875 cellular metal ion homeostasis
GO:0006878 cellular copper ion homeostasis
GO:0006887 exocytosis
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006892 post-Golgi vesicle-mediated transport
GO:0006898 receptor-mediated endocytosis
GO:0006900 membrane budding
GO:0007015 actin filament organization
GO:0007033 vacuole organization
GO:0007034 vacuolar transport
GO:0007040 lysosome organization
GO:0007041 lysosomal transport
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0008654 phospholipid biosynthetic process
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0010720 positive regulation of cell development
GO:0010765 positive regulation of sodium ion transport
GO:0010959 regulation of metal ion transport
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0015672 monovalent inorganic cation transport
GO:0016050 vesicle organization
GO:0016197 endosomal transport
GO:0016358 dendrite development
GO:0017156 calcium ion regulated exocytosis
GO:0017157 regulation of exocytosis
GO:0017158 regulation of calcium ion-dependent exocytosis
GO:0019216 regulation of lipid metabolic process
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0030041 actin filament polymerization
GO:0030100 regulation of endocytosis
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031334 positive regulation of protein complex assembly
GO:0031346 positive regulation of cell projection organization
GO:0031623 receptor internalization
GO:0032271 regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0034314 Arp2/3 complex-mediated actin nucleation
GO:0034315 regulation of Arp2/3 complex-mediated actin nucleation
GO:0034377 plasma lipoprotein particle assembly
GO:0034379 very-low-density lipoprotein particle assembly
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035725 sodium ion transmembrane transport
GO:0043112 receptor metabolic process
GO:0043254 regulation of protein complex assembly
GO:0043270 positive regulation of ion transport
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044089 positive regulation of cellular component biogenesis
GO:0045010 actin nucleation
GO:0045017 glycerolipid biosynthetic process
GO:0045055 regulated exocytosis
GO:0045324 late endosome to vacuole transport
GO:0045666 positive regulation of neuron differentiation
GO:0045807 positive regulation of endocytosis
GO:0045921 positive regulation of exocytosis
GO:0045956 positive regulation of calcium ion-dependent exocytosis
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046916 cellular transition metal ion homeostasis
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048167 regulation of synaptic plasticity
GO:0048193 Golgi vesicle transport
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048489 synaptic vesicle transport
GO:0050688 regulation of defense response to virus
GO:0050690 regulation of defense response to virus by virus
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050769 positive regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050792 regulation of viral process
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0051047 positive regulation of secretion
GO:0051125 regulation of actin nucleation
GO:0051222 positive regulation of protein transport
GO:0051258 protein polymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051607 defense response to virus
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051962 positive regulation of nervous system development
GO:0055070 copper ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0055108 Golgi to transport vesicle transport
GO:0060292 long term synaptic depression
GO:0060627 regulation of vesicle-mediated transport
GO:0060628 regulation of ER to Golgi vesicle-mediated transport
GO:0060996 dendritic spine development
GO:0060998 regulation of dendritic spine development
GO:0060999 positive regulation of dendritic spine development
GO:0065005 protein-lipid complex assembly
GO:0070142 synaptic vesicle budding
GO:0071825 protein-lipid complex subunit organization
GO:0071827 plasma lipoprotein particle organization
GO:0080171 lytic vacuole organization
GO:0090066 regulation of anatomical structure size
GO:0097006 regulation of plasma lipoprotein particle levels
GO:0097061 dendritic spine organization
GO:0097212 lysosomal membrane organization
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0098542 defense response to other organism
GO:1900006 positive regulation of dendrite development
GO:1902305 regulation of sodium ion transmembrane transport
GO:1902307 positive regulation of sodium ion transmembrane transport
GO:1902774 late endosome to lysosome transport
GO:1902822 regulation of late endosome to lysosome transport
GO:1902824 positive regulation of late endosome to lysosome transport
GO:1902953 positive regulation of ER to Golgi vesicle-mediated transport
GO:1903305 regulation of regulated secretory pathway
GO:1903307 positive regulation of regulated secretory pathway
GO:1903335 regulation of vacuolar transport
GO:1903337 positive regulation of vacuolar transport
GO:1903532 positive regulation of secretion by cell
GO:1903725 regulation of phospholipid metabolic process
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0000287 magnesium ion binding
GO:0003924 GTPase activity
GO:0005057 receptor signaling protein activity
GO:0005525 GTP binding
GO:0008047 enzyme activator activity
GO:0016004 phospholipase activator activity
GO:0019001 guanyl nucleotide binding
GO:0019003 GDP binding
GO:0032561 guanyl ribonucleotide binding
GO:0060229 lipase activator activity
GO:1990583 phospholipase D activator activity
Cellular Component GO:0005770 late endosome
GO:0005777 peroxisome
GO:0005778 peroxisomal membrane
GO:0005798 Golgi-associated vesicle
GO:0005802 trans-Golgi network
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0014069 postsynaptic density
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030055 cell-substrate junction
GO:0030135 coated vesicle
GO:0030137 COPI-coated vesicle
GO:0031252 cell leading edge
GO:0031903 microbody membrane
GO:0031984 organelle subcompartment
GO:0042579 microbody
GO:0043292 contractile fiber
GO:0044438 microbody part
GO:0044439 peroxisomal part
GO:0044449 contractile fiber part
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
GO:0098791 Golgi subcompartment
GO:0098794 postsynapse
GO:0099572 postsynaptic specialization
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-421837: Clathrin derived vesicle budding
R-HSA-1643685: Disease
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-162906: HIV Infection
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-6811438: Intra-Golgi traffic
R-HSA-432720: Lysosome Vesicle Biogenesis
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-167590: Nef Mediated CD4 Down-regulation
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-1483255: PI Metabolism
R-HSA-1483257: Phospholipid metabolism
R-HSA-597592: Post-translational protein modification
R-HSA-1660514: Synthesis of PIPs at the Golgi membrane
R-HSA-1660499: Synthesis of PIPs at the plasma membrane
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ARF1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23804711Chronic Lymphocytic LeukemiaInhibit immunityTransendothelial migration (TEM) of normal lymphocytes into lymph nodes requires the chemokine-induced activation of Rap1 and αLβ2 integrin. However, in most cases of CLL, Rap1 is refractory to chemokine stimulation, resulting in failed αLβ2 activation and TEM unless α4β1 is coexpressed. In this study, we show that the inability of CXCL12 to induce Rap1 GTP loading in CLL cells results from failure of Rap1-containing endosomes to translocate to the plasma membrane. Taken together, our findings indicate that chemokine unresponsiveness in CLL lymphocytes results from failure of Arf1/phospholipase D1-mediated translocation of Rap1 to the plasma membrane for GTP loading and may be a specific feature of anergy induced by DNA Ags.
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0540.779
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0430.991
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0630.982
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3770.52
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0510.982
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9250.759
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0250.961
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3960.866
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3470.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2650.915
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5420.889
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1460.036
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARF1
NameADP-ribosylation factor 1
Aliases
Chromosomal Location1q42.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARF1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ARF1.
ID Name Drug Type Targets #Targets
DB027741,3-PropandiolSmall MoleculeARF11
DB04121Guanosine-3'-Monophosphate-5'-DiphosphateSmall MoleculeARF11
DB04137Guanosine-5'-TriphosphateSmall MoleculeADSSL1, ARF1, GLUD1, HRAS, PFKFB1, RAB5A, RAP2A, RHEB, RND3, UCKL110
DB04315Guanosine-5'-DiphosphateSmall MoleculeADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......36
DB07348Brefeldin ASmall MoleculeARF1, CYTH22
DB08231Myristic acidSmall MoleculeABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......20
DB09462GlycerinSmall MoleculeADH1B, ARF1, GSTP1, HPGDS, ISYNA1, ITPR1, NAGA, PAEP, PAPSS1, PLA2 ......13